1. Cardiac Biomarkers

2. Cost of Heart Failure to Society

3. Biomarkers in the Management of Heart Failure Challenges and Opportunities

4. BNP and NT-proBNP for Diagnosis or Exclusion of Heart Failure

5. Correlations of Natriuretic Peptides With Cardiac Structure and Function

6. The Differential Diagnosis of an Elevated BNP or NT-proBNP

7. BNP and NT-proBNP for Prognosis in Heart Failure

8. Biomarker-Guided Heart Failure Trials

9. Understanding Heterogeneous Results in “Guided Therapy” Trials

10. TIME CHF Cost-Effectiveness BNP-Guided Therapy

13. Dallas Heart Study

14. High-Sensitivity Troponin Use in Europe

15. Troponins and Risk Stratification in Stable Outpatient CAD

17. Secondary Prevention and Prognostic Value of High-Sensitivity Troponins

18. Biomarker Assessments in Stable Patients With T2DM Observations From the SAVOR-TIMI 53 Trial

19. ADVANCE Trial

20. Cardiovascular Mortality Risk According to Number of Elevated Biomarkers

21. Additive Value of ST2 to NT-proBNP in Long-Term Prognosis

22. Prognosis Value of BNP/NT-proBNP Based on Timing of Measurement During Index Hospitalization for Acute HF

23. Therapies That Affect B-Type Natriuretic Peptide Levels

24. Neprilysin Inhibition A New Paradigm for HF Care?

25. LCZ696 and Biomarkers

26. Biomarkers and Risk Assessment

27. AMI

28. 6 Million Chest Pain Visits Evaluated Annually in the United States

29. Can We Do Better?

30. Three Clinical Evaluation Tools

31. APACE hs-cTnT 1-Hour Algorithm

32. Patient Inclusion/Exclusion Criteria

33. TRAPID-AMI Results Presented at ESC 2014

34. Clinical Implications

35. Could Older Adults Be at Greater Risk of a “False Positive” Diagnosis of AMI?

36. Key Clinical Points

37. References

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)